Have you ever wondered why some people develop chronic diseases despite doing everything “right”—eating well, exercising regularly, and managing stress—while others seem resilient? The answer may lie in a protein you've probably never heard of: galectin-3.

As a functional medicine physician who has spent decades investigating the root causes of complex chronic illnesses, I've come to recognize galectin-3 as one of the most important biomarkers we're not routinely measuring. This multifunctional protein plays a central role in inflammation, fibrosis, heart disease, cancer progression, neurodegeneration, and immune dysfunction. When galectin-3 levels become elevated, it can set in motion a cascade of pathological processes that drive accelerated aging and chronic disease—similar to what we see with mast cell activation syndrome and other chronic inflammatory conditions.

Today, I want to share with you the science of galectin-3, why elevated levels are so problematic, and—most importantly—what you can do to address it through evidence-based diet, lifestyle, and targeted nutritional interventions.

What Is Galectin-3?

Galectin-3 is a beta-galactoside-binding lectin—a protein that binds to sugar molecules on cell surfaces and in the extracellular matrix. It's the only member of the “chimeric” galectin family, distinguished by its unique structure: a carbohydrate recognition domain (CRD) connected to an unusual proline-and glycine-rich N-terminal domain that allows it to form oligomers.

Galectin-3 is found throughout the body—in the nucleus, cytoplasm, on cell surfaces, and in biological fluids like blood and urine. It participates in a remarkable range of biological processes including cell adhesion, immune regulation, apoptosis (programmed cell death), inflammation, fibrosis, and tissue repair.

Under normal circumstances, galectin-3 serves protective functions. However, when it becomes chronically elevated or dysregulated, it transforms from a helpful mediator into a pathological driver of disease.

The Dark Side of Elevated Galectin-3

Research over the past two decades has revealed that elevated galectin-3 levels are associated with—and actively promote—numerous disease processes:

Heart Disease and Cardiac Fibrosis

Galectin-3 has been extensively studied in cardiovascular disease. It's secreted by activated macrophages in the heart and promotes cardiac fibrosis by activating fibroblasts to produce excessive collagen and scar tissue. This progressive cardiac fibrosis contributes to heart failure, ventricular remodeling, and decreased cardiac function.

Studies have consistently shown that elevated circulating galectin-3 levels predict heart failure events and all-cause mortality. In fact, levels above 17.8 ng/mL are associated with significantly increased risk of death or hospitalization in patients with chronic heart failure. Galectin-3 is now FDA-approved as a prognostic biomarker for heart failure risk assessment.

Beyond heart failure, research published in Arteriosclerosis, Thrombosis, and Vascular Biology demonstrated that galectin-3 is upregulated in unstable atherosclerotic plaques and acts as an amplifier of inflammation, promoting monocyte recruitment and macrophage activation—key processes in plaque progression.

Inflammation and Immune Dysfunction

Galectin-3 is increasingly recognized as a master regulator of inflammation. It promotes pro-inflammatory cytokine production including IL-1β, IL-6, TNF-α, and IL-18. Research has shown that galectin-3 activates the NLRP3 inflammasome—a critical component of the innate immune system that, when chronically activated, drives systemic inflammation. These are the same inflammatory pathways I've discussed in relation to GLP-1 agonists and their anti-inflammatory effects.

A 2023 review in Trends in Pharmacological Sciences highlighted galectin-3 as a key player in cardiac, hepatic, renal, and pulmonary inflammation and fibrosis, as well as neuroinflammatory disorders. The protein's ability to perpetuate inflammation makes it a crucial target for inflammatory disease management.

Organ Fibrosis

Perhaps galectin-3's most damaging effect is its role in promoting fibrosis across multiple organs. Research has linked elevated galectin-3 to:

• Liver fibrosis and non-alcoholic steatohepatitis (NASH)
• Kidney fibrosis and chronic kidney disease progression
• Pulmonary fibrosis (idiopathic pulmonary fibrosis)
• Cardiac fibrosis and heart failure

Animal studies have shown that galectin-3 knockout mice are protected from developing fibrosis in response to injury, while mice with elevated galectin-3 develop severe fibrotic changes. This provides compelling evidence that galectin-3 is not just a biomarker, but a primary driver of fibrogenesis. Environmental toxins like mold toxins can trigger galectin-3 elevation and contribute to organ fibrosis. The fibrotic process shares similarities with inflammation-induced fibrin production, where chronic inflammation leads to tissue damage and scarring.

Cancer Progression and Metastasis

Galectin-3 plays a complex role in cancer biology. Tumor cells often overexpress galectin-3, using it to:

• Evade immune surveillance by suppressing T cell and NK cell function
• Promote angiogenesis (blood vessel formation to feed tumors)
• Facilitate metastasis by enhancing cancer cell adhesion and migration
• Resist apoptosis and chemotherapy

Research has documented galectin-3 overexpression in numerous cancers including breast, colon, thyroid, prostate, and ovarian cancers. Higher galectin-3 levels are generally associated with more aggressive disease and poorer prognosis, though the relationship varies by cancer type.

Neurodegeneration and Brain Aging

Emerging research links galectin-3 to neurodegenerative diseases and accelerated brain aging. Galectin-3 is expressed by activated microglia (the brain's immune cells) and promotes neuroinflammation. Studies have found:

• Elevated galectin-3 in Alzheimer's disease brain tissue and cerebrospinal fluid
• Increased galectin-3 in Huntington's disease, correlating with disease severity
• Higher plasma galectin-3 in amyotrophic lateral sclerosis (ALS) patients
• Association with stroke severity and poor outcomes following intracerebral hemorrhage

A fascinating 2019 study published in Nature Communications demonstrated that galectin-3 accumulates at damaged lysosomes in Huntington's disease microglia, prevents clearance of cellular debris, and promotes inflammation through NF-κB and NLRP3 inflammasome-dependent pathways. Remarkably, knocking down galectin-3 suppressed inflammation, reduced protein aggregation, restored neuronal function, and improved survival in mouse models.

Metabolic Dysfunction

Galectin-3 is implicated in metabolic dysregulation, particularly insulin resistance and type 2 diabetes. Research suggests that extracellular galectin-3 may bind directly to the insulin receptor and attenuate insulin signaling. Studies have also shown that galectin-3 knockout mice fed a high-fat diet are protected from developing insulin resistance compared to normal mice.

A 2025 review in the journal Genes examining galectin-3 across cardiovascular health domains found that high-fat diets significantly increase galectin-3 expression and activate inflammatory pathways including the NLRP3 inflammasome via TLR4, heightening inflammatory processes and contributing to metabolic disease. This connection between inflammation and metabolic dysfunction is also seen in conditions like mast cell activation syndrome, where chronic inflammation drives widespread metabolic disruption.

Testing Galectin-3: What You Need to Know

Galectin-3 can be measured through a simple blood test. Several commercial assays are available, including the FDA-cleared ARCHITECT Galectin-3 assay. Normal reference ranges typically consider levels below 17.8 ng/mL as low risk, though some research suggests optimal levels may be even lower.

In my practice, I measure galectin-3 in patients with:

• Known or suspected heart disease
• Chronic inflammatory conditions
• Autoimmune diseases
• Unexplained fatigue or systemic symptoms
• History of cancer or high cancer risk
• Cognitive decline or neurodegenerative disease
• Kidney or liver disease

It's important to note that galectin-3 levels remain relatively stable over time and don't fluctuate with acute decompensation, making it a useful marker for underlying disease processes rather than acute events.

Evidence-Based Strategies to Lower Galectin-3

The good news is that galectin-3 levels are modifiable through targeted interventions. Here's what the science tells us about reducing galectin-3 and its harmful effects:

Modified Citrus Pectin: The Primary Galectin-3 Inhibitor

Modified citrus pectin (MCP) is the most well-researched natural galectin-3 inhibitor. MCP is derived from the inner white pith of citrus fruit peels through enzymatic modification that breaks long pectin chains into smaller fragments (typically under 15 kDa molecular weight). This modification is critical because unmodified pectin cannot be absorbed through the intestinal lining.

MCP works by binding directly to galectin-3's carbohydrate recognition domain, preventing it from interacting with its biological targets. One of the most extensively studied formulations is PectaSol-C Modified Citrus Pectin, which has demonstrated benefits in numerous clinical trials. Extensive research has demonstrated MCP's benefits:

Cardiovascular Protection: Animal studies have shown that MCP reduces cardiac lipotoxicity in obesity, prevents cardiac fibrosis, and reduces atherosclerotic lesion formation. A study published in PLOS One found that MCP reduced atherosclerotic lesion size by approximately 50% in mice by inhibiting monocyte adhesion to endothelial cells.

Kidney Protection: Research in experimental acute kidney injury showed that MCP reduced renal cell proliferation, decreased galectin-3 expression, and reduced renal fibrosis, apoptosis, and inflammatory markers during recovery.

Anti-Cancer Effects: Multiple studies have demonstrated that MCP inhibits cancer cell adhesion, reduces metastasis in animal models of melanoma, breast, colon, and prostate cancer, and may sensitize tumors to chemotherapy.

Neurological Benefits: Research published in Stroke showed that MCP prevented blood-brain barrier disruption in subarachnoid hemorrhage models by inhibiting galectin-3.

Anti-Inflammatory Effects: A 2025 study in Frontiers in Pharmacology demonstrated that MCP ameliorated methotrexate-induced liver and lung toxicity through modulation of galectin-3 and multiple inflammatory pathways including NF-κB and TGF-β signaling.

The typical therapeutic dose of MCP ranges from 5-15 grams daily, though clinical trials have used varying protocols. The most studied commercial preparation is PectaSol-C Modified Citrus Pectin, which is available in powder form for flexible dosing. Work with your functional medicine practitioner to determine the appropriate dose for your individual needs. MCP is most effective when combined with comprehensive anti-inflammatory support including omega-3 fatty acids and polyphenol-rich nutrients.

Anti-Inflammatory Diet

Diet profoundly influences galectin-3 levels. Research has consistently shown that:

High-Fat Diets Increase Galectin-3: Studies demonstrate that diets high in saturated fats and processed foods significantly increase galectin-3 expression and activate pro-inflammatory pathways. Animal research shows that high-fat diets induce galectin-3 expression and activate the NLRP3 inflammasome.

Mediterranean Diet Reduces Galectin-3: The Mediterranean dietary pattern, rich in vegetables, fruits, whole grains, legumes, nuts, olive oil, and fish while low in red meat, has been associated with lower inflammatory markers. Research shows that limiting saturated fat intake may reduce chronic inflammatory and fibrotic processes mediated by galectin-3.

Green Mediterranean Diet Shows Remarkable Benefits: A groundbreaking 2025 study published in Clinical Nutrition examined the DIRECT PLUS trial and found compelling evidence that diet can directly influence proteins in the galectin family. In this 18-month randomized controlled trial, 294 participants were assigned to one of three dietary interventions:

• Healthy dietary guidelines (control group)
• Mediterranean diet with 440 mg/day polyphenols from walnuts
• Green Mediterranean diet with 1,240 mg/day polyphenols from walnuts, Mankai (duckweed aquatic plant), and green tea—while minimizing red and processed meat

Using advanced MRI brain scans and proteomics analysis of 87 serum proteins, researchers discovered that higher levels of galectin-9 and decorin were associated with accelerated brain aging (a larger “brain age gap”). Remarkably, participants following the green Mediterranean diet experienced:

• Significantly reduced galectin-9 levels over the 18-month intervention
• Slowed increase in decorin compared to other diet groups
• Attenuated brain aging as measured by MRI-based brain age calculation

While this study focused on galectin-9 rather than galectin-3, the findings are highly relevant because galectin-9, like galectin-3, is expressed in microglial cells in the brain and promotes neuroinflammation by binding to the Tim-3 receptor and inducing pro-inflammatory cytokines. The fact that a high-polyphenol, plant-forward diet significantly reduced galectin-9 suggests that similar dietary patterns may beneficially modulate the entire galectin family, including galectin-3.

The key components of the neuroprotective green Mediterranean diet included:

• 3-4 cups of green tea daily (rich in polyphenols, particularly EGCG)
• 28 grams of walnuts daily (providing omega-3 ALA and polyphenols)
• Mankai green shakes (100 grams frozen cubes providing concentrated polyphenols)
• Abundant vegetables and fruits
• Extra virgin olive oil as primary fat
• Very low or no red/processed meat

The anti-inflammatory activity of these polyphenol-rich components appears to modulate galectin proteins and slow brain aging through multiple mechanisms including reduced oxidative stress, decreased inflammatory cytokine production, and improved metabolic health.

Based on the research, I recommend a dietary approach that includes:

• Abundant colorful vegetables and fruits high in polyphenols
• Daily green tea consumption (3-4 cups)
• Omega-3 rich fatty fish 2-3 times weekly
• Raw walnuts and other nuts/seeds (1-2 ounces daily)
• Extra virgin olive oil as primary fat source
• Legumes and whole grains
• Fermented foods to support gut health
• Minimal red meat and complete avoidance of processed meats
• Limited refined carbohydrates and added sugars

Regular Exercise

Physical activity appears to modulate galectin-3 in complex ways. Research published in a 2025 review found that:

• Intense, short-term exercise can transiently increase galectin-3, likely reflecting adaptive cardiovascular changes
• Regular exercise, particularly aerobic training and high-intensity interval training (HIIT), tends to reduce galectin-3 concentrations over time
• Exercise-induced galectin-3 reduction suggests a role in long-term cardiovascular and cognitive protection

I recommend a combination of moderate-intensity aerobic exercise (30-45 minutes, 5 days weekly) with resistance training (2-3 days weekly) and occasional HIIT sessions for optimal metabolic and anti-inflammatory benefits.

Targeted Nutritional Support

Beyond MCP, several other nutritional interventions may help modulate inflammation and fibrosis:

Omega-3 Fatty Acids: EPA and DHA reduce inflammatory cytokines and have anti-fibrotic properties. I typically recommend 2-4 grams daily of high-quality fish oil. For optimal results, I recommend purified omega-3 supplements like Dr. Jill Health Omega Essentials 950, which provides concentrated EPA and DHA in their natural triglyceride form for superior absorption. This premium fish oil is sourced from the clean waters off the Chilean coast and independently tested to ensure purity.

Curcumin: This powerful anti-inflammatory compound inhibits NF-κB and NLRP3 inflammasome activation—pathways through which galectin-3 exerts its inflammatory effects. I've formulated Dr. Jill Health Super Turmeric, which provides a comprehensive blend of turmeric phytonutrients that target multiple proinflammatory pathways. For combined benefits, Dr. Jill Health Omega Curcumin offers the synergistic power of highly bioavailable omega-3s and curcumin in a single formula, addressing both the inflammatory cytokines and the NF-κB/NLRP3 pathways that galectin-3 activates.

Vitamin D: Adequate vitamin D status is essential for immune regulation and inflammation control. Aim for blood levels of 60-80 ng/mL.

N-Acetylcysteine (NAC): This precursor to glutathione supports antioxidant defenses and may help counter oxidative stress associated with elevated galectin-3.

Resveratrol and Other Polyphenols: Plant polyphenols from berries, green tea, and grapes have anti-inflammatory and potentially anti-fibrotic properties.

Dr. Jill's Top Supplement Recommendations for Galectin-3 Support

For Comprehensive Anti-Inflammatory Support:

• Dr. Jill Health Omega Curcumin – Combines highly bioavailable omega-3s with BCM-95® curcumin to simultaneously address inflammatory cytokines AND inhibit the NF-κB/NLRP3 pathways that galectin-3 activates. This is my go-to combination formula.
• Dr. Jill Health Omega Essentials 950 – High-concentration, purified fish oil providing 950mg EPA/DHA per softgel in natural triglyceride form. Sourced from pristine Chilean waters and tested for purity. Take 2-4 capsules daily for optimal anti-inflammatory benefits.
• Dr. Jill Health Super Turmeric – A comprehensive blend of turmeric phytonutrients specifically formulated to target multiple proinflammatory pathways and support immune function.

For Modified Citrus Pectin (Direct Galectin-3 Inhibition):

• PectaSol-C Modified Citrus Pectin – The most extensively researched modified citrus pectin formula, clinically proven to bind galectin-3 and reduce its harmful effects. Available in unflavored powder for flexible dosing (5-15 grams daily, divided into 2-3 doses).

Note: These supplements work best as part of a comprehensive protocol that includes an anti-inflammatory diet, regular exercise, stress management, and addressing root causes of inflammation.

Optimize Gut Health

Since galectin-3 plays a role in intestinal inflammation and is influenced by the gut microbiome, supporting gut health is essential:

• Consume prebiotic fibers to feed beneficial bacteria
• Include probiotic-rich fermented foods
• Consider a high-quality multi-strain probiotic supplement
• Support gut barrier function with L-glutamine and zinc carnosine
• Address any underlying dysbiosis, SIBO, or intestinal infections

Manage Stress

Chronic stress drives inflammation and likely increases galectin-3 expression. Implement stress management practices including:

• Daily meditation or prayer
• Adequate sleep (7-9 hours nightly)
• Mind-body practices like yoga or tai chi
• Time in nature
• Connection with supportive community

Clinical Application: A Functional Medicine Approach

In my practice, when I identify elevated galectin-3 levels, I implement a comprehensive protocol:

1. Test and Monitor: Establish baseline galectin-3 levels and identify associated conditions. Retest after 3-6 months of intervention.

2. Address Root Causes: Identify and treat underlying drivers such as chronic infections, environmental toxin exposure and chronic inflammation, metabolic dysfunction, or autoimmune processes.

3. Implement Modified Citrus Pectin: Begin with 5-15 grams daily of high-quality MCP such as PectaSol-C, typically in divided doses.

4. Optimize Diet: Transition to an anti-inflammatory, Mediterranean-style or green Mediterranean dietary pattern rich in polyphenols and low in processed foods and red meat.

5. Support with Targeted Nutrients: Add omega-3s, curcumin, vitamin D, and other anti-inflammatory compounds based on individual needs.

6. Enhance Lifestyle Factors: Implement regular exercise, stress management, and sleep optimization.

7. Monitor Progress: Track symptoms, functional status, and relevant biomarkers including galectin-3, inflammatory markers, and organ-specific indicators.

A Word About Hope

If you've been struggling with chronic illness—whether heart disease, autoimmune conditions, unexplained inflammation, or concerning symptoms that haven't been fully explained—measuring and addressing galectin-3 may provide crucial insights and open new pathways to healing.

What I find most encouraging about galectin-3 research is that this isn't a marker we're powerless to change. Unlike genetic factors we can't modify, galectin-3 responds to interventions. Through targeted use of modified citrus pectin, anti-inflammatory dietary patterns, regular exercise, and comprehensive lifestyle optimization, we can reduce galectin-3 and potentially interrupt the pathological processes it drives.

This represents a fundamental principle of functional medicine: identify the upstream drivers of disease, and address them at their source. Galectin-3 is increasingly recognized as one of those crucial upstream factors—a protein that sits at the intersection of inflammation, fibrosis, immune dysfunction, and chronic disease.

If you're working with complex chronic illness, I encourage you to partner with a functional medicine practitioner who can help you investigate galectin-3 and other emerging biomarkers, identify your unique root causes, and create a personalized protocol to restore health. Your body has a profound capacity for healing when we remove what's harming it and provide what it needs to thrive.

References

1. Mackinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012;185(5):537-546. https://pubmed.ncbi.nlm.nih.gov/22095546/
2. Henderson NC, Mackinnon AC, Farnworth SL, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci USA. 2006;103(13):5060-5065. https://pubmed.ncbi.nlm.nih.gov/16549783/
3. Dumic J, Dabelic S, Flögel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006;1760(4):616-635. https://pubmed.ncbi.nlm.nih.gov/16478649/
4. de Boer RA, Lok DJ, Jaarsma T, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011;43(1):60-68. https://pubmed.ncbi.nlm.nih.gov/21248255/
5. Lok DJ, Van Der Meer P, de la Porte PW, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010;99(5):323-328. https://pubmed.ncbi.nlm.nih.gov/20130888/
6. Papaspyridonos M, McNeill E, de Bono JP, et al. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol. 2008;28(3):433-440. https://www.ahajournals.org/doi/10.1161/atvbaha.107.159160
7. Delacour D, Koch A, Jacob R. The role of galectins in protein trafficking. Traffic. 2009;10(10):1405-1413. https://pubmed.ncbi.nlm.nih.gov/19761541/
8. Cunn Y, Zhang X, Liu B, et al. Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington's disease. Nat Commun. 2019;10(1):3473. https://www.nature.com/articles/s41467-019-11441-0
9. Wang X, Zhang S, Lin F, Chu W, Yue S. Elevated galectin-3 levels in the serum of patients with Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2015;30(8):729-732. https://pubmed.ncbi.nlm.nih.gov/25795565/
10. Yan J, Xu Y, Zhang L, et al. Increased expressions of plasma galectin-3 in patients with amyotrophic lateral sclerosis. Chin Med J (Engl). 2016;129(23):2797-2803. https://pubmed.ncbi.nlm.nih.gov/27900991/
11. Kolatsi-Joannou M, Price KL, Winyard PJ, Long DA. Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury. PLoS One. 2011;6(4):e18683. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0018683
12. Lau ES, Liu E, Paniagua SM, et al. Galectin-3 inhibition with modified citrus pectin in hypertension. JACC Basic Transl Sci. 2021;6(1):12-21. https://www.jacc.org/doi/10.1016/j.jacbts.2020.10.006
13. Traber PG, Zomer E. Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS One. 2013;8(12):e83481. https://pubmed.ncbi.nlm.nih.gov/24349519/
14. Iacobini C, Menini S, Ricci C, et al. Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver. J Hepatol. 2011;54(5):975-983. https://pubmed.ncbi.nlm.nih.gov/21145801/
15. Nangia-Makker P, Hogan V, Honjo Y, et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst. 2002;94(24):1854-1862. https://pubmed.ncbi.nlm.nih.gov/12488479/
16. Platt D, Raz A. Modulation of the lung colonization of B16-F1 melanoma cells by citrus pectin. J Natl Cancer Inst. 1992;84(6):438-442. https://pubmed.ncbi.nlm.nih.gov/1538421/
17. Suthahar N, Meijers WC, Silljé HHW, et al. Galectin-3 activation and inhibition in heart failure and cardiovascular disease: an update. Theranostics. 2018;8(3):593-609. https://www.thno.org/v08p0593.htm
18. Nishikawa H, Liu L, Nakano F, et al. Modified citrus pectin prevents blood-brain barrier disruption in mouse subarachnoid hemorrhage by inhibiting galectin-3. Stroke. 2018;49(11):2743-2751. https://www.ahajournals.org/doi/10.1161/strokeaha.118.021757
19. Bouz-Sorra J, McHenry S, Carlyle B, et al. Modified citrus pectin ameliorates methotrexate-induced hepatic and pulmonary toxicity: role of Nrf2, galectin-3/TLR-4/NF-κB/TNF-α and TGF-β signaling pathways. Front Pharmacol. 2025;15:1528978. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1528978/full
20. MacKinnon AC, Liu X, Hadoke PW, et al. Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice. Glycobiology. 2013;23(6):654-663. https://pmc.ncbi.nlm.nih.gov/articles/PMC3641797/
21. Kaplan A, Zelicha H, Tsaban G, et al. The effect of a high-polyphenol Mediterranean diet (green-MED) combined with physical activity on age-related brain atrophy: the DIRECT PLUS trial. Am J Clin Nutr. 2022;115(5):1270-1281. https://pubmed.ncbi.nlm.nih.gov/35134825/
22. Pachter D, Yaskolka Meir A, Kaplan A, et al. Serum galectin-9 and decorin in relation to brain aging and the green-Mediterranean diet: a secondary analysis of the DIRECT PLUS randomized trial. Clin Nutr. 2025;44(3):235-244. https://www.sciencedirect.com/science/article/pii/S0261561425002353
23. Fani L, Wolters FJ, Cremers LGM, et al. Galectin-3 and cardiovascular disease in the community. Arterioscler Thromb Vasc Biol. 2022;42(12):1540-1549. https://www.ahajournals.org/doi/10.1161/ATVBAHA.122.318340
24. Vergaro G, Del Franco A, Giannoni A, et al. Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy. Int J Cardiol. 2015;184:96-100. https://pubmed.ncbi.nlm.nih.gov/25705010/
25. Delgado-Olguín P, Hernández-Hernández JM, Dillmann WH. Galectin-3: a novel biomarker and therapeutic target for heart failure. Rev Esp Cardiol (Engl Ed). 2013;66(8):613-620. https://pubmed.ncbi.nlm.nih.gov/24776328/
26. Henderson NC, Sethi T. The regulation of inflammation by galectin-3. Immunol Rev. 2009;230(1):160-171. https://pubmed.ncbi.nlm.nih.gov/19594635/

Disclaimer: This article is for educational purposes only and is not intended as medical advice. Galectin-3 testing and treatment should be supervised by a qualified healthcare provider. Always consult with your physician before making changes to your treatment plan or beginning new supplements.